Ruxolitinib Plus Chemotherapy as Pre/Postsurgical Treatment in Ovarian Cancer Appears FeasibleJune 6th 2022
A neoadjuvant and postsurgical treatment regimen involving ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer.
Pembrolizumab Plus Chemotherapy With or Without Bevacizumab Consistently Improves Survival in Advanced Cervical Cancer SubgroupsJune 6th 2022
Results from the phase 3 KEYNOTE-826 trial show a significant survival benefit with pembrolizumab plus chemotherapy with or without bevacizumab in most patient subgroups with persistent, recurrent, or metastatic cervical cancer.
First-Line Rucaparib Maintenance Improves PFS in Ovarian Cancer, Regardless of HRD StatusJune 6th 2022
The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.
Platinum-Agnostic Ovarian Cancer in Recurrent Setting May Benefit from Mirvetuximab Soravtansine/BevacizumabJune 7th 2021
Results reported at the 2021 ASCO Annual Meeting show that half of patients treated in the FORWARD II trial achieved a response to therapy with mirvetuximab soravtansine and bevacizumab.
Shannon N. Westin, MD, MPH, Discussed the Wee1 Inhibitor Adavosertib for PARPi-Resistant Ovarian CancerJune 5th 2021
CancerNetwork® sat down with Shannon N. Westin, MD, MPH, at the 2021 ASCO Annual Meeting to talk about the use of adavosertib in PARP inhibitor–resistant ovarian cancer.
Multi-Trial Analysis Indicates Niraparib Maintenance for BRCA+ Ovarian Cancer Leads to PFS Benefit Across SettingsJune 4th 2021
Data presented at the 2021 ASCO Annual Meeting on 3 prominent trials of niraparib as maintenance for ovarian cancer after a positive response to platinum-based chemotherapy further support the use of the agent in multiple settings.
Karen H. Lu, MD, on Genetic Testing From Patients’ Living RoomsJuly 6th 2020
At the 2020 ASCO Virtual Scientific Program, Karen H. Lu, MD, presented on findings from the MAGENTA trial, designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.
Phase 3 SOLO2/ENGOT-ov21 Trial Shows Promise for Maintenance Olaparib in Ovarian CancerJune 29th 2020
The results of the trial demonstrated that maintenance olaparib provided an unprecedented improvement in median OS versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Andres Poveda, MD, on the Phase III SOLO2/ENGOT-ov21 Final OS Data in Ovarian CancerJune 4th 2020
Final overall survival results from the trial showed that maintenance olaparib provided an unprecedented improvement in median overall survival versus placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Addition of Cediranib to Olaparib Fails to Induce Superior PFS in Platinum-Censitive Ovarian CancerMay 31st 2020
A phase III study using cediranib and olaparib to treat recurrent platinum-sensitive ovarian cancer did not meet its primary endpoint of progression-free survival but did produce comparable activity to standard of care platinum-based chemotherapy treatment.
Mirvetuximab Soravtansine Combination Yields Encouraging Response Rates in Ovarian CancerMay 30th 2020
A study presented at the 2020 ASCO Scientific Program combining mirvetuximab soravtansine with bevacizumab to treat platinum-agnostic ovarian cancer demonstrated an encouraging overall response rate and tolerability profile regardless of platinum status.